Patents by Inventor Martin Prlic

Martin Prlic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12152252
    Abstract: Systems and methods to modulate the function of mucosal-associated invariant T (MAIT) cells in the absence of a T cell receptor (TCR) signal are described. The systems and methods can be used to elucidate the function of MAIT cells to assess potential therapeutic strategies for conditions associated with inflammation.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: November 26, 2024
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Martin Prlic, Julia Berkson, Chloe Slichter
  • Publication number: 20230398150
    Abstract: The disclosure provides compositions and related methods for detecting, inhibiting, reducing or killing tumor-infiltrating regulatory T cells (Tregs) characterized by expression of inducible T cell costimulator (ICOS) and Interleukin-1 receptor type 1 (IL-1R1). The reagents can include a bi-specific affinity reagent with a first domain that specifically binds ICOS and a second domain that specifically binds IL-1R1 or, separately, a first affinity reagent that specifically binds ICOS and a second affinity reagent that specifically binds IL-1R1. In some embodiments, the reagent can comprise engineered immune cells expressing a first chimeric antigen receptor (CAR) specific for ICOS and a second CAR specific for IL-1R1, wherein the cell requires binding by the first CAR and second CAR to activate, such as a logic-gated CAR T cell.
    Type: Application
    Filed: October 14, 2021
    Publication date: December 14, 2023
    Applicant: FRED HUTCHINSON CANCER CENTER
    Inventors: Martin Prlic, Florian Mair, Jami R. Erickson
  • Patent number: 10815290
    Abstract: Single chain, multimerized, and/or glycosylated NKG2D decoys are described. The NKG2D decoys have high affinity and avidity for surface bound and soluble NKG2D ligands and can be used to (i) identify NKG2D ligands; (ii) treat cancer, graft vs. host disease (GVHD), and inflammatory conditions; and (iii) potentiate an immune response against a vaccine as well as many other potential uses.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: October 27, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Mesfin Gewe, Roland K. Strong, Martin Prlic, Peter Rupert, Thomas Spies, Veronika Spies
  • Publication number: 20190382725
    Abstract: Systems and methods to modulate the function of mucosal-associated invariant T (MAIT) cells in the absence of a T cell receptor (TCR) signal are described. The systems and methods can be used to elucidate the function of MAIT cells to assess potential therapeutic strategies for conditions associated with inflammation.
    Type: Application
    Filed: January 23, 2018
    Publication date: December 19, 2019
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Martin Prlic, Julia Berkson, Chloe Slichter
  • Publication number: 20180371051
    Abstract: Single chain, multimerized, and/or glycosylated NKG2D decoys are described. The NKG2D decoys have high affinity and avidity for surface bound and soluble NKG2D ligands and can be used to (i) identify NKG2D ligands; (ii) treat cancer, graft vs. host disease (GVHD), and inflammatory conditions; and (iii) potentiate an immune response against a vaccine as well as many other potential uses.
    Type: Application
    Filed: November 10, 2016
    Publication date: December 27, 2018
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Roland K. Strong, Mesfin Gewe, Martin Prlic, Peter Rupert, Thomas Spies, Veronika Spies